2026 Q2 - tulosraportti
Vain PDF
34 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 364 | - | - | ||
| 2 000 | - | - | ||
| 2 932 | - | - | ||
| 1 449 | - | - | ||
| 3 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenMedical cannabis faces a bright future because intensive research is being conducted into whether medical cannabis is at least as good as or better than various types of medicine that have many and severe side effects. Researchers have begun to publish the results of the various studies. They have apparently been at it for many years, because the research results from this long-term study have shown that the drop in the use of opioid medications was a full 90%. As well as that this study confirms the same thing we just heard, that there were no notable side effects from using medical cannabis. https://www.marijuanamoment.net/medical-marijuana-improves-lower-back-back-pain-and-reduces-opioid-use-new-10-year-study-shows/- ·13 t sittenStock status. Now it's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch). Now the pharmacy in Hamburg reports being sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that Weeco Astrum10/10 has been sold out at several pharmacies since July 30, 2026, and that the pharmacies that have permission for it have bought internally. So we must expect a company announcement in about a month, stating that there are problems with the delivery, and maybe we will get the completely correct reason. So we won't have to guess a reason for this, which might be wrong.
@3D Do you have access to the pharmacies' inventory management? Summary: at the general meeting, it was pointed out that NO, as in absolutely NO, significant sales were expected in Germany this year. Hope to see you at the next general meeting, as the announcements so far are consistent with the real picture regarding Germany. The board and management and the few shareholders who attend would like to meet more shareholders at the general meeting. - ·2 päivää sittenI think it's soon time for TS to say thank you for now and find another place to be, which is not a commercial company, because it's clear that he has peaked at Stenocare, and that the chairman of the board Marianne Wier finds a new CEO who understands communication and who can safely lead Stenocare into the commercial world. The news that the revenue from sales of Cannabis medicine in Denmark is increasing has already been broken by Jhonnykuskus on September 11, by inserting an image on the topic, and on September 14, I, with a link to the article, informed that there have only been three reports of side effects caused by cannabis medicine. If the above news had come from TS first and just as it was published, there would be an opportunity for the stock to rise, because it is the management that points out that it is good for their product, and the future sales of Astrum10/10. But these important news, have come from us investors, 10 days ago. It is not to be overlooked that the chairman of the board Marianne Wier, together with the board, must start looking for a new CEO who understands communication and can lead Stenocare into the next phase, which is the commercial part. https://www.nordnet.dk/markedet/nyheder/07e59bfc-7b77-4901-a252-805c775383dd
·15.9.Does anyone have an idea about the trading pattern we are seeing right now. It seems a bit mysterious that sales are being made at prices lower than the highest bid price and sales are being made at prices far above the lowest ask price (in fact, at a selling price so high that it cannot be seen in the 5 available ask offers) It doesn't even make sense if it were day traders, because they usually trade the other way.
As far as I can see, all trades happen in EXACTLY the interval that is in the order book? At least today. 1000 units were bought at 0.928 and 50 were sold down to 0.878. I imagine that the price is being kept down a bit as many new investors perhaps don't understand that one does not sell at the % increase one sees but at the nearest Buy order, so when the Spread between buy and sell is 0.05 kr, it quickly moves the price by about 5%.
·11.9.ExcitingJohnny, I can read and unlike you and 3D, I am able to be critical. You believe that the price of stenocare rises just because you write a lot of positive nonsense, for which there is no basis. But again, just invest according to 3D's recommendations... if you can afford it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 111 270 | 111 270 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 111 270 | 111 270 | 0 | 0 |
2026 Q2 - tulosraportti
Vain PDF
34 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenMedical cannabis faces a bright future because intensive research is being conducted into whether medical cannabis is at least as good as or better than various types of medicine that have many and severe side effects. Researchers have begun to publish the results of the various studies. They have apparently been at it for many years, because the research results from this long-term study have shown that the drop in the use of opioid medications was a full 90%. As well as that this study confirms the same thing we just heard, that there were no notable side effects from using medical cannabis. https://www.marijuanamoment.net/medical-marijuana-improves-lower-back-back-pain-and-reduces-opioid-use-new-10-year-study-shows/
- ·13 t sittenStock status. Now it's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch). Now the pharmacy in Hamburg reports being sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that Weeco Astrum10/10 has been sold out at several pharmacies since July 30, 2026, and that the pharmacies that have permission for it have bought internally. So we must expect a company announcement in about a month, stating that there are problems with the delivery, and maybe we will get the completely correct reason. So we won't have to guess a reason for this, which might be wrong.@3D Do you have access to the pharmacies' inventory management? Summary: at the general meeting, it was pointed out that NO, as in absolutely NO, significant sales were expected in Germany this year. Hope to see you at the next general meeting, as the announcements so far are consistent with the real picture regarding Germany. The board and management and the few shareholders who attend would like to meet more shareholders at the general meeting.
- ·2 päivää sittenI think it's soon time for TS to say thank you for now and find another place to be, which is not a commercial company, because it's clear that he has peaked at Stenocare, and that the chairman of the board Marianne Wier finds a new CEO who understands communication and who can safely lead Stenocare into the commercial world. The news that the revenue from sales of Cannabis medicine in Denmark is increasing has already been broken by Jhonnykuskus on September 11, by inserting an image on the topic, and on September 14, I, with a link to the article, informed that there have only been three reports of side effects caused by cannabis medicine. If the above news had come from TS first and just as it was published, there would be an opportunity for the stock to rise, because it is the management that points out that it is good for their product, and the future sales of Astrum10/10. But these important news, have come from us investors, 10 days ago. It is not to be overlooked that the chairman of the board Marianne Wier, together with the board, must start looking for a new CEO who understands communication and can lead Stenocare into the next phase, which is the commercial part. https://www.nordnet.dk/markedet/nyheder/07e59bfc-7b77-4901-a252-805c775383dd
- ·15.9.Does anyone have an idea about the trading pattern we are seeing right now. It seems a bit mysterious that sales are being made at prices lower than the highest bid price and sales are being made at prices far above the lowest ask price (in fact, at a selling price so high that it cannot be seen in the 5 available ask offers) It doesn't even make sense if it were day traders, because they usually trade the other way.As far as I can see, all trades happen in EXACTLY the interval that is in the order book? At least today. 1000 units were bought at 0.928 and 50 were sold down to 0.878. I imagine that the price is being kept down a bit as many new investors perhaps don't understand that one does not sell at the % increase one sees but at the nearest Buy order, so when the Spread between buy and sell is 0.05 kr, it quickly moves the price by about 5%.
- ·11.9.ExcitingJohnny, I can read and unlike you and 3D, I am able to be critical. You believe that the price of stenocare rises just because you write a lot of positive nonsense, for which there is no basis. But again, just invest according to 3D's recommendations... if you can afford it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 364 | - | - | ||
| 2 000 | - | - | ||
| 2 932 | - | - | ||
| 1 449 | - | - | ||
| 3 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 111 270 | 111 270 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 111 270 | 111 270 | 0 | 0 |
2026 Q2 - tulosraportti
Vain PDF
34 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenMedical cannabis faces a bright future because intensive research is being conducted into whether medical cannabis is at least as good as or better than various types of medicine that have many and severe side effects. Researchers have begun to publish the results of the various studies. They have apparently been at it for many years, because the research results from this long-term study have shown that the drop in the use of opioid medications was a full 90%. As well as that this study confirms the same thing we just heard, that there were no notable side effects from using medical cannabis. https://www.marijuanamoment.net/medical-marijuana-improves-lower-back-back-pain-and-reduces-opioid-use-new-10-year-study-shows/
- ·13 t sittenStock status. Now it's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch). Now the pharmacy in Hamburg reports being sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that Weeco Astrum10/10 has been sold out at several pharmacies since July 30, 2026, and that the pharmacies that have permission for it have bought internally. So we must expect a company announcement in about a month, stating that there are problems with the delivery, and maybe we will get the completely correct reason. So we won't have to guess a reason for this, which might be wrong.@3D Do you have access to the pharmacies' inventory management? Summary: at the general meeting, it was pointed out that NO, as in absolutely NO, significant sales were expected in Germany this year. Hope to see you at the next general meeting, as the announcements so far are consistent with the real picture regarding Germany. The board and management and the few shareholders who attend would like to meet more shareholders at the general meeting.
- ·2 päivää sittenI think it's soon time for TS to say thank you for now and find another place to be, which is not a commercial company, because it's clear that he has peaked at Stenocare, and that the chairman of the board Marianne Wier finds a new CEO who understands communication and who can safely lead Stenocare into the commercial world. The news that the revenue from sales of Cannabis medicine in Denmark is increasing has already been broken by Jhonnykuskus on September 11, by inserting an image on the topic, and on September 14, I, with a link to the article, informed that there have only been three reports of side effects caused by cannabis medicine. If the above news had come from TS first and just as it was published, there would be an opportunity for the stock to rise, because it is the management that points out that it is good for their product, and the future sales of Astrum10/10. But these important news, have come from us investors, 10 days ago. It is not to be overlooked that the chairman of the board Marianne Wier, together with the board, must start looking for a new CEO who understands communication and can lead Stenocare into the next phase, which is the commercial part. https://www.nordnet.dk/markedet/nyheder/07e59bfc-7b77-4901-a252-805c775383dd
- ·15.9.Does anyone have an idea about the trading pattern we are seeing right now. It seems a bit mysterious that sales are being made at prices lower than the highest bid price and sales are being made at prices far above the lowest ask price (in fact, at a selling price so high that it cannot be seen in the 5 available ask offers) It doesn't even make sense if it were day traders, because they usually trade the other way.As far as I can see, all trades happen in EXACTLY the interval that is in the order book? At least today. 1000 units were bought at 0.928 and 50 were sold down to 0.878. I imagine that the price is being kept down a bit as many new investors perhaps don't understand that one does not sell at the % increase one sees but at the nearest Buy order, so when the Spread between buy and sell is 0.05 kr, it quickly moves the price by about 5%.
- ·11.9.ExcitingJohnny, I can read and unlike you and 3D, I am able to be critical. You believe that the price of stenocare rises just because you write a lot of positive nonsense, for which there is no basis. But again, just invest according to 3D's recommendations... if you can afford it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 364 | - | - | ||
| 2 000 | - | - | ||
| 2 932 | - | - | ||
| 1 449 | - | - | ||
| 3 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 111 270 | 111 270 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 111 270 | 111 270 | 0 | 0 |